Around 100 operational workers from the Port of Maputo (Maputo Port Development Society – MPDC) took part last Saturday in an open discussion on HIV prevention led by C-Saúde, with a focus on Lenacapavir, a new long-acting injectable prevention option that provides protection against HIV for six months with a single dose.
The initiative aimed to answer questions and promote dialogue around the different HIV prevention options available in Mozambique, reinforcing a simple message: when people have access to clear information and a range of alternatives, they are better equipped to choose the method — or combination of methods — that best suits their circumstances and needs.
The session was marked by active participation, thoughtful questions and the sharing of experiences, highlighting the importance of bringing high-quality health and prevention information into the workplace.
C-Saúde is a partner of Mozambique’s Ministry of Health in the implementation of Lenacapavir in Zambézia Province, where the provision of this prevention method began on 29 April 2026. Beyond Zambézia, through the voluntary efforts of its members, C-Saúde continues to promote this innovative option, which has the potential to make a significant contribution to controlling the HIV epidemic. Mozambique is among a pioneering group of nine African countries that are introducing Lenacapavir this year.
Our thanks to the Port of Maputo and to all the employees who took part in this conversation and helped create an open space for learning, reflection and dialogue on HIV prevention.
This success story is made possible by the generous support of the United States Government.
